Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Anaplastic Thyroid Cancer Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Anaplastic Thyroid Cancer Overview | 8 | 1 |
| Pipeline Products for Anaplastic Thyroid Cancer Comparative Analysis | 9 | 1 |
| Anaplastic Thyroid Cancer Therapeutics under Development by Companies | 10 | 1 |
| Anaplastic Thyroid Cancer Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Anaplastic Thyroid Cancer Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Anaplastic Thyroid Cancer Products under Development by Companies | 14 | 1 |
| Anaplastic Thyroid Cancer Products under Investigation by Universities/Institutes | 15 | 1 |
| Anaplastic Thyroid Cancer Companies Involved in Therapeutics Development | 16 | 8 |
| Daiichi Sankyo Company, Limited | 16 | 1 |
| Genelux Corporation | 17 | 1 |
| Immune Pharmaceuticals Inc. | 18 | 1 |
| Millennium Pharmaceuticals Inc | 19 | 1 |
| Novartis AG | 20 | 1 |
| Pfizer Inc. | 21 | 1 |
| Plexxikon Inc. | 22 | 1 |
| Trophogen, Inc. | 23 | 1 |
| Anaplastic Thyroid Cancer Therapeutics Assessment | 24 | 10 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Combination Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 36 |
| ceritinib Drug Profile | 34 | 5 |
| CLM-3 Drug Profile | 39 | 1 |
| crizotinib Drug Profile | 40 | 7 |
| crolibulin Drug Profile | 47 | 2 |
| dabrafenib mesylate + trametinib dimethyl sulfoxide Drug Profile | 49 | 6 |
| efatutazone Drug Profile | 55 | 2 |
| GLONC-2 Drug Profile | 57 | 1 |
| GLV-1h153 Drug Profile | 58 | 1 |
| pexidartinib Drug Profile | 59 | 4 |
| PLX-8394 Drug Profile | 63 | 1 |
| Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing Drug Profile | 64 | 1 |
| sapanisertib Drug Profile | 65 | 3 |
| utomilumab Drug Profile | 68 | 2 |
| Anaplastic Thyroid Cancer Dormant Projects | 70 | 1 |
| Anaplastic Thyroid Cancer Product Development Milestones | 71 | 1 |
| Featured News &Press Releases | 71 | 1 |
| Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds | 71 | 1 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |